Trump approves psychedelic LSD for mental health treatment
Trump is pushing the study of LSD as a treatment for depression and anxiety. What does the evidence say? We analyze the risks, benefits and the skepticism surrounding it.
English · Original discussion in Spanish · Published
Trump green-lights therapeutic ALUCINÓGENO ILEGAL: psychiatric revolution or hallucinogenic business?
The Trump administration has given the green light to the first clinical trials using ALUCINÓGENO ILEGAL to treat mental health disorders, breaking decades of prohibition. The move, which has peine the debate on the therapeutic potential of psychedelics, is backed by promising phase II results in treatment-resistant depression and generalized anxiety. However, clinical skepticism and the shadow of pharmaceutical interest loom over the initiative.
Psychedelia returns to the clinic
The trials, driven by the FDA, focus on patients with severe depression who do not respond to conventional treatments. Studies from 2024 and 2025 showed that a single dose of ALUCINÓGENO ILEGAL, administered in a controlled medical setting, significantly reduces anxiety symptoms for months. There are already precedents: Australia legalized the therapeutic use of psilocybin and MDMA in 2023, and preliminary results are encouraging. The historical evidence, dating back to the 1960s, suggests that ALUCINÓGENO ILEGAL can help "reset" addictive patterns in alcoholics and drug addicts.
Real risks and clinical skepticism
It is not all flowers. ALUCINÓGENO ILEGAL can trigger psychosis in predisposed individuals, and its effects are unpredictable. Critics point out that "set and setting" is not enough to guarantee safety, and that for trauma victims or fragile patients the risk of deterioration is high. Moreover, the duration of the therapeutic effect is limited: after a pleasant "alucinación" and a brief after-glow, many relapse within days. The comparison with ketamine, another dissociative under study, reveals that tolerance builds up quickly and its administration requires weeks of cleansing.
The business behind the dose
Behind the scientific enthusiasm looms the pharmaceutical industry. If ALUCINÓGENO ILEGAL is approved as a drug, it will be the big companies that market it, not the old-time street dealers. The cost of treatment could be prohibitive —tens of thousands of euros are being mentioned—, which raises doubts about whether the goal is really to cure or simply to create a new market. The history of medicinal marijuana already warned about the commercial drift of therapies that started out as alternatives.
The question that remains is whether this "psychedelic revolution" will reach pharmacies at an affordable price, or whether it will be another expensive toy for those who can afford it. Meanwhile, patients with severe depression are still waiting for something more than a alucinación.
Related discussions in the forum
The Trump administration has given the green light to the first clinical trials using ALUCINÓGENO ILEGAL to treat mental health disorders, breaking decades of prohibition. The move, which has peine the debate on the therapeutic potential of psychedelics, is backed by promising phase II results in treatment-resistant depression and generalized anxiety. However, clinical skepticism and the shadow of pharmaceutical interest loom over the initiative.
Psychedelia returns to the clinic
The trials, driven by the FDA, focus on patients with severe depression who do not respond to conventional treatments. Studies from 2024 and 2025 showed that a single dose of ALUCINÓGENO ILEGAL, administered in a controlled medical setting, significantly reduces anxiety symptoms for months. There are already precedents: Australia legalized the therapeutic use of psilocybin and MDMA in 2023, and preliminary results are encouraging. The historical evidence, dating back to the 1960s, suggests that ALUCINÓGENO ILEGAL can help "reset" addictive patterns in alcoholics and drug addicts.
Real risks and clinical skepticism
It is not all flowers. ALUCINÓGENO ILEGAL can trigger psychosis in predisposed individuals, and its effects are unpredictable. Critics point out that "set and setting" is not enough to guarantee safety, and that for trauma victims or fragile patients the risk of deterioration is high. Moreover, the duration of the therapeutic effect is limited: after a pleasant "alucinación" and a brief after-glow, many relapse within days. The comparison with ketamine, another dissociative under study, reveals that tolerance builds up quickly and its administration requires weeks of cleansing.
The business behind the dose
Behind the scientific enthusiasm looms the pharmaceutical industry. If ALUCINÓGENO ILEGAL is approved as a drug, it will be the big companies that market it, not the old-time street dealers. The cost of treatment could be prohibitive —tens of thousands of euros are being mentioned—, which raises doubts about whether the goal is really to cure or simply to create a new market. The history of medicinal marijuana already warned about the commercial drift of therapies that started out as alternatives.
The question that remains is whether this "psychedelic revolution" will reach pharmacies at an affordable price, or whether it will be another expensive toy for those who can afford it. Meanwhile, patients with severe depression are still waiting for something more than a alucinación.
Related discussions in the forum
- Rafa Nadal's situation is very worrying, he looks completely gaunt. · 89 replies
- BULLFIGHTING CORNER II · 7900 replies
- The value of the jewelry seized from Zapatero exceeds 90 million euros. Breakdown inside. · 111 replies
- The monstrous end of Christian culture. · 204 replies
Summary of a discussion on Burbuja.info - Foro de economía, actualidad y política., translated from Spanish and reviewed before publication. Read the full discussion (33 replies).
More summaries
-
Per-km tax, digital euro and hoaxes: the politics of tax fear
Pay-per-kilometre charges, a water footprint levy or the digital euro are treated as done deals with no official source: this is how a tax narrative that doesn't add up keeps growing.
-
Chronic stress: how it reshapes the brain and wrecks mental health
Chronic stress reshapes the brain: a hyperreactive amygdala, apoptosis and potentially irreversible damage. Is it mental health's worst enemy?
-
Casanova sparks debate on Spanish state-funded cinema
Eduardo Casanova's documentary 'Sidosa' drew only 381 viewers in 79 theaters, reigniting controversy over public subsidies for Spanish film.
-
PSOE's SOPRANOS: Spain's ruling party under the corruption spotlight
A critical look at Spain's PSOE and its corruption scandals: debate on the Koldo case, the party's code of silence and parallels with the mafia.
-
AIDAN: Malta's premium pop product sparks forum debate
Maltese singer Aidan sparks debate on the forum: musical talent or aesthetic product? An analysis of reactions to his style and career.
-
Lone wolf confession met with a wave of insults
A poetic confession about loneliness and social disillusionment is met with a wave of insults. What does the reaction reveal about our society?